Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LFWD
LFWD logo

LFWD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
7.680
Open
7.090
VWAP
7.48
Vol
13.75K
Mkt Cap
21.61M
Low
7.090
Amount
102.88K
EV/EBITDA(TTM)
--
Total Shares
2.81M
EV
18.23M
EV/OCF(TTM)
--
P/S(TTM)
0.51
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
Show More

Events Timeline

(ET)
2026-05-19
08:30:00
Lifeward Appoints Keith Rose as Chief Medical Officer
select
2026-04-27 (ET)
2026-04-27
17:10:00
Lifeward Files to Sell 7.26M Ordinary Shares
select
2026-03-25 (ET)
2026-03-25
16:50:00
Lifeward Closes Strategic Partnership with Oramed
select
2026-03-18 (ET)
2026-03-18
08:10:00
Lifeward Reports Q4 Revenue of $5.1M, CEO Highlights Strategic Investment
select
2026-03-13 (ET)
2026-03-13
08:20:00
Lifeward Shareholders Approve Partnership with Oramed
select
2026-03-02 (ET)
2026-03-02
08:30:00
Lifeward Partners with Shirley Ryan AbilityLab for ReWalk Exoskeleton Clinics
select
2026-02-25 (ET)
2026-02-25
08:20:00
Lifeward Acquires Skelable Technology Assets for $480,000
select
2026-02-23 (ET)
2026-02-23
20:00:00
Rewalk Robotics LTD Trading Halted, News Pending
select

News

NASDAQ.COM
2.0
05-21NASDAQ.COM
Lifeward (LFWD) Q4 2025 Earnings Transcript
NASDAQ.COM
5.0
05-19NASDAQ.COM
Lifeward Appoints New Chief Medical Officer
  • Executive Appointment: Lifeward Ltd. announced the appointment of Keith Rose as Chief Medical Officer, who previously served as Vice President of Medical Affairs and Medical Director of Neurosciences, tasked with leading the company's global medical strategy, which is expected to drive further advancements in the medical technology sector.
  • Extensive Experience: Keith Rose brings over 30 years of experience in rehabilitation medicine, neuroscience, and medical affairs, having held senior medical affairs and clinical leadership roles at Biocodex, Novocure, Ipsen Bioscience, Jazz Pharmaceuticals, and Indivior, which will provide Lifeward with valuable industry insights and expertise.
  • Strategic Expansion: CEO Mark Grant stated that this appointment supports the company's efforts to expand its rehabilitation technology portfolio and advance newly acquired biomedical assets, demonstrating the company's strategic ambitions in the medical technology field.
  • Market Reaction: Following the announcement, Lifeward's stock closed down 1.79% at $6.58 on Nasdaq, reflecting a cautious market sentiment regarding the company's future developments.
seekingalpha
9.5
05-15seekingalpha
Lifeward Ltd. Q1 2026 Earnings Call Insights
  • Acquisition Milestone: Lifeward successfully completed the acquisition of Oratech in Q1 2026, strengthening its position as a diversified biomedical innovation company focused on neurorehabilitation, while maintaining minimal near-term operational burden.
  • Financial Performance Review: Revenue for Q1 2026 was $3.9 million, down from $5 million in Q1 2025, primarily impacted by working capital constraints, although ReWalk personal exoskeleton sales increased by 11% year-over-year to $1.6 million.
  • Liquidity Enhancement: Lifeward significantly improved its balance sheet with $10 million from convertible note financing, ending the quarter with $11.4 million in unrestricted cash and cash equivalents, a substantial increase from $2.2 million at the end of 2025.
  • Cautious Future Outlook: Management expects overall revenue for 2026 to be similar to 2025 despite a weaker Q1, expressing optimism for sales growth in the coming months, particularly driven by a backlog of AlterG orders.
seekingalpha
9.5
05-15seekingalpha
Lifeward Reports Q1 Loss with Revenue Decline
  • Earnings Loss: Lifeward reported a Q1 Non-GAAP EPS of -$3.13 with revenue of $3.92 million, reflecting a 22.1% year-over-year decline and missing expectations by $1.86 million, indicating significant competitive pressure on the company.
  • Improved Cash Position: As of March 31, 2026, Lifeward had $11.4 million in unrestricted cash and cash equivalents, a substantial increase from $2.2 million as of December 31, 2025, demonstrating progress in financial management.
  • Operational Efficiency Gains: Cash used in operating activities decreased to $3.7 million in Q1 2026 from $5.5 million in Q1 2025, primarily due to improved operational efficiencies and working capital management, highlighting effective cost control measures.
  • Strategic Expansion Signals: Lifeward is signaling a strategic expansion into oral insulin and AI-powered rehabilitation through a partnership with Oramed, indicating a proactive approach to entering new markets and enhancing future growth potential.
seekingalpha
9.5
05-14seekingalpha
Lifeward Q1 Earnings Announcement Scheduled
  • Earnings Release Date: Lifeward (LFWD) is set to announce its Q1 earnings on May 15th after market close, with a consensus EPS estimate of -$0.34, reflecting a 22.7% year-over-year improvement, indicating the company's efforts to enhance financial performance amid challenges.
  • Revenue Expectations: The anticipated revenue for Q1 is $5.78 million, representing a 14.9% year-over-year increase, which, despite existing challenges, demonstrates some growth potential and reflects the company's adaptability in the market.
  • Historical Performance: Over the past two years, Lifeward has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating difficulties in meeting financial targets, which may impact investor confidence.
  • Strategic Partnership: Lifeward's collaboration with Oramed signifies a strategic expansion into oral insulin and AI-powered rehabilitation, suggesting that despite current financial struggles, this initiative could lay the groundwork for future growth.
Newsfilter
9.5
05-11Newsfilter
Lifeward to Report Q1 2026 Financial Results on May 15
  • Earnings Announcement: Lifeward will release its Q1 2026 financial results before U.S. markets open on May 15, reflecting the company's ongoing commitment to transparency and investor communication.
  • Executive Conference Call: Following the earnings release, CEO Mark Grant and CFO Almog Adar will host a conference call at 8:30 a.m. EDT to provide in-depth analysis of the financial results and address investor inquiries.
  • Product Portfolio Overview: Lifeward's portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton and AlterG® Anti-Gravity System, showcasing the company's strong position in biomedical innovation.
  • Strategic Transformation: The company is evolving into a diversified biomedical firm, expanding into high-value therapeutic platforms, particularly its oral delivery system targeting the diabetes market, indicating a focus on future growth opportunities.
Wall Street analysts forecast LFWD stock price to rise
1 Analyst Rating
Wall Street analysts forecast LFWD stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
4.50
Averages
4.50
High
4.50
Current: 0.000
sliders
Low
4.50
Averages
4.50
High
4.50
H.C. Wainwright
NULL -> Buy
maintain
$10
AI Analysis
2026-03-19
Reason
H.C. Wainwright
Price Target
$10
AI Analysis
2026-03-19
maintain
NULL -> Buy
Reason
H.C. Wainwright adjusted the firm's price target on Lifeward to $10 from $4.50 and keeps a Buy rating on the shares. The firm cites the company's 1-12 reverse stock split for the target change.
H.C. Wainwright
Swayampakula Ramakanth
Buy
downgrade
$13
2025-11-18
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$13
2025-11-18
downgrade
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Lifeward to $4.50 from $13 and keeps a Buy rating on the shares following the Q3 report. The firm says the company's operational changes, regulatory wins and changes in payor dynamics underway bode well for future growth.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LFWD
Unlock Now

Valuation Metrics

The current forward P/E ratio for Lifeward Ltd (LFWD.O) is 0.00, compared to its 5-year average forward P/E of -3.32. For a more detailed relative valuation and DCF analysis to assess Lifeward Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.32
Current PE
0.00
Overvalued PE
-1.43
Undervalued PE
-5.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.03
Current EV/EBITDA
-0.31
Overvalued EV/EBITDA
0.53
Undervalued EV/EBITDA
-0.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.39
Current PS
0.43
Overvalued PS
7.23
Undervalued PS
-0.44

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks bearish tomorrow sell
Intellectia · 26 candidates
Relative Vol: >= 1.50Moving Average Relationship: PriceBelowMA5, PriceBelowMA20Is Optionable: TrueOne Day Rise Prob: <= 50.00One Day Predict Return: <= 0.0%Macd: bearish
Ticker
Name
Market Cap$
top bottom
XPOF logo
XPOF
Xponential Fitness Inc
320.79M
TNDM logo
TNDM
Tandem Diabetes Care Inc
1.27B
TOST logo
TOST
Toast Inc
17.03B
TSSI logo
TSSI
TSS Inc
457.15M
IRS logo
IRS
IRSA Inversiones y Representaciones SA
1.13B
TRDA logo
TRDA
Entrada Therapeutics Inc
265.53M

Whales Holding LFWD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Lifeward Ltd (LFWD) stock price today?

The current price of LFWD is 7.68 USD — it has decreased -3.4

What is Lifeward Ltd (LFWD)'s business?

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

What is the price predicton of LFWD Stock?

Wall Street analysts forecast LFWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFWD is4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Lifeward Ltd (LFWD)'s revenue for the last quarter?

Lifeward Ltd revenue for the last quarter amounts to 3.92M USD, decreased -22.07

What is Lifeward Ltd (LFWD)'s earnings per share (EPS) for the last quarter?

Lifeward Ltd. EPS for the last quarter amounts to -6.70 USD, increased 21.16

How many employees does Lifeward Ltd (LFWD). have?

Lifeward Ltd (LFWD) has 81 emplpoyees as of June 03 2026.

What is Lifeward Ltd (LFWD) market cap?

Today LFWD has the market capitalization of 21.61M USD.